Abediterol has higher bronchodilatory potency than other long-acting beta2-receptor agonists in a guinea pig model

J. De Alba, R. Otal, J. A. Fernández-Blanco, M. Aparici, C. Puig, A. Gavaldà, M. Miralpeix (Barcelona, Spain)

Source: International Congress 2014 – Novel evidence relating to respiratory treatment development
Session: Novel evidence relating to respiratory treatment development
Session type: Thematic Poster Session
Number: 951
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
J. De Alba, R. Otal, J. A. Fernández-Blanco, M. Aparici, C. Puig, A. Gavaldà, M. Miralpeix (Barcelona, Spain). Abediterol has higher bronchodilatory potency than other long-acting beta2-receptor agonists in a guinea pig model. Eur Respir J 2014; 44: Suppl. 58, 951

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Abediterol has higher beta2-receptor affinity and in vitro bronchodilatory potency than other long-acting beta2-agonists, with good selectivity
Source: International Congress 2014 – Novel evidence relating to respiratory treatment development
Year: 2014

Abediterol has higher bronchodilatory potency and reduced cardiac effects versus other long-acting beta2-agonists in dogs
Source: International Congress 2014 – Rationale behind respiratory drug development
Year: 2014

Bronchoprotective activity and safety assessment of two novel dual-acting MABA compounds (LAS190792 and LAS191351) in dogs
Source: International Congress 2014 – Novel targets and drugs for asthma and COPD
Year: 2014

The inverse agonist propranolol does not confer steroid-sparing activity in persistent asthma
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014


The dual PDE3/PDE4 phosphodiesterase inhibitor RPL554 produces more complete bronchodilator responses than the beta2-agonist salbutamol and the anti-muscarinic agent ipratropium bromide, alone and in combination, in guinea-pig isolated trachea
Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis
Year: 2015


Repeated-dose pharmacokinetics of once-daily TD-4208, a long-acting muscarinic receptor antagonist (LAMA), in subjects with COPD
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014


Abediterol, a novel long-acting inhaled beta2-agonist, has a fast association rate and long residence time at human beta2 receptors
Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases
Year: 2014

Synergistic bronchoprotective activity of the long-acting beta 2-agonist olodaterol with tiotropium (long-acting M3 antagonist) and ciclesonide (inhaled steroid) on the ovalbumin-induced bronchoconstriction in anaesthetized guinea pigs
Source: Annual Congress 2011 - Understanding disease and drug mechanisms
Year: 2011


A novel dual-agonist challenge model in guinea pigs for assessment of individual and combined muscarinics antagonists and b2 adrenoceptor agonists bronchodilator efficacy
Source: Annual Congress 2011 - Models of disease and drug actions
Year: 2011

Inhaled roflumilast and tadalafil supress airway reactivity and inflammation in ovalbumin-sensitized guinea pigs
Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action
Year: 2016

Synergistic effects by combination of tiotropium with olodaterol result from cross talk between muscarinic and β2-adrenergic receptors via allosteric modulation
Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action
Year: 2016


Effects of the new ultra-long-acting β2-AR agonist indacaterol in chronic treatment alone or in combination with the β1-AR blocker metoprolol on cardiac remodelling
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015

Ciclesonide and tiotropium synergistically inhibit airway eosinophilia in a guinea pig model of chronic asthma
Source: Annual Congress 2013 –Novel mechanisms for established drugs for asthma and COPD management
Year: 2013

Effect of the CYP3A4 inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of AZD5069, an oral CXCR2 antagonist
Source: International Congress 2014 – Novel evidence relating to respiratory treatment development
Year: 2014

Long-lasting interaction study between RPL554 and glycopyrronium bromide on human isolated bronchi
Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases
Year: 2014

Efficacy and safety of abediterol, a long-acting beta2-adrenergic agonist (LABA); three phase II trials in asthma
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014

Anti-inflammatory effects of histamine H1-receptor antagonist and leukotriene CysLT1-receptor antagonist in patients with atopic asthma maintained on inhaled corticosteroids
Source: Eur Respir J 2004; 24: Suppl. 48, 221s
Year: 2004

Bronchodilator activity of the combination of salbutamol hemisuccinate and methatropium iodide compared with monotherapy in preclinical studies
Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis
Year: 2015

Pharmacological profile of a novel, potent and oral TRPA1 antagonist. Characterization in a preclinical model of induced cough
Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis
Year: 2015

CRAC channel inhibition by RP3128 ameliorates airway hyper-reactivity in antigen sensitized mice and guinea pigs
Source: International Congress 2014 – Novel targets and drugs for asthma and COPD
Year: 2014